{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:43:20Z","timestamp":1791945800293,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009416","name":"Institute of Conservation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xjidi.2023.100230","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:39:56Z","timestamp":1694644796000},"page":"100230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-5157","authenticated-orcid":false,"given":"Michael D.","family":"Howell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1329-7272","authenticated-orcid":false,"given":"Fiona I.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0614-5230","authenticated-orcid":false,"given":"Beth","family":"Rumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5409-0011","authenticated-orcid":false,"given":"Erika","family":"Boarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-6351","authenticated-orcid":false,"given":"Kang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-0846","authenticated-orcid":false,"given":"Kathleen","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-6430","authenticated-orcid":false,"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-756X","authenticated-orcid":false,"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-0708","authenticated-orcid":false,"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2023.100230_bib1","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Statist Sci"},{"key":"10.1016\/j.xjidi.2023.100230_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40257-013-0039-3","article-title":"The role of tumor necrosis factor-\u03b1 in the pathogenesis of vitiligo","volume":"14","author":"Camara-Lemarroy","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.13128","article-title":"Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2","volume":"72","author":"Drucker","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2023.100230_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2249.2004.02570.x","article-title":"Interleukin-16 expression and release in bullous pemphigoid","volume":"137","author":"Frezzolini","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family [published correction appears in Nat Rev Immunol 2009;9:747","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.146027","article-title":"Meta-analysis for association of TNFA-308(G > A) SNP with vitiligo susceptibility","volume":"809","author":"Giri","year":"2022","journal-title":"Gene"},{"key":"10.1016\/j.xjidi.2023.100230_bib12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jaad.2021.05.047","article-title":"Efficacy of Ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial","volume":"86","author":"Hamzavi","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib13","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A\u00a0mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor Ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/13685538.2020.1806814","article-title":"Levels of TNF-\u03b1, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo","volume":"23","author":"Karag\u00fcn","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.xjidi.2023.100230_bib16","first-page":"519","article-title":"IL-16 expression is increased in the skin and sera of patients with systemic sclerosis","volume":"59","author":"Kawabata","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2023.100230_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with Ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of Ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0161-5890(97)00052-7","article-title":"The \u2013308 tumor necrosis factor-\u03b1 promoter polymorphism effects transcription","volume":"34","author":"Kroeger","year":"1997","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A\u00a0review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kr\u00fcger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jaad.2022.02.062","article-title":"Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: a nationwide population-based study","volume":"87","author":"Lim","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through JAK signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2010.01.016","article-title":"IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis","volume":"125","author":"Meyer","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2023.100230_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib25","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/bjd.15933","article-title":"Quality of life in people with vitiligo: a systematic review and meta-analysis","volume":"177","author":"Morrison","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib26","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1016\/S0021-9258(18)66992-3","article-title":"H+ coupled uphill transport of aminocephalosporins via the dipeptide transport system in rabbit intestinal brush-border membranes","volume":"261","author":"Okano","year":"1986","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xjidi.2023.100230_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of Ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/jdv.15255","article-title":"Association of vitiligo with hospitalization for mental health disorders in US adults","volume":"33","author":"Patel","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2023.100230_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165577","article-title":"Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease","volume":"11","author":"Purzycka-Bohdan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2023.100230_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.IJD_300_20","article-title":"The study of serum level of interleukin-2, interleukin-6, and tumor necrosis factor-\u03b1 in stable and progressive vitiligo patients from SINA Hospital in Tabriz, Iran","volume":"66","author":"Ranjkesh","year":"2021","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib31","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xjidi.2023.100230_bib32","first-page":"343","article-title":"Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.xjidi.2023.100230_bib33","doi-asserted-by":"crossref","first-page":"R531","DOI":"10.1016\/S0960-9822(01)00312-8","article-title":"Cytokines: il-20 - a new effector in skin inflammation","volume":"11","author":"Rich","year":"2001","journal-title":"Curr Biol"},{"key":"10.1016\/j.xjidi.2023.100230_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2023.100230_bib37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100230_bib38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor Ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000354607","article-title":"Comorbidities associated with vitiligo: a ten-year retrospective study","volume":"227","author":"Sheth","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100230_bib40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","article-title":"Association between vitiligo extent and distribution and quality-of-life impairment","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155432","article-title":"Tumor necrosis factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo","volume":"140","author":"Singh","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.xjidi.2023.100230_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo-new insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J\u00a0Cosmet Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/bjd.15458","article-title":"Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa","volume":"177","author":"Thomi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100230_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5114\/ada.2022.113612","article-title":"Increased serum levels of interleukin-17 in patients with alopecia areata and non-segmental vitiligo","volume":"39","author":"Tomaszewska","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.xjidi.2023.100230_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:05:04Z","timestamp":1763021104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026723000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2667026723000565"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100230","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100230"}}